Actively Recruiting
Comparing Quarterly Injectable Letrozole SIE to Daily Oral Letrozole Femara4 in Post-Menopausal Women with Hormone Receptor-Positive Early Breast Cancer
Led by Rovi Pharmaceuticals Laboratories · Updated on 2026-10-09
120
Participants Needed
21
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying post-menopausal women who have been treated for hormone receptor-positive early breast cancer. The study compares the amount of the drug letrozole in the bloodstream after multiple doses of a quarterly injectable form called Letrozole SIE to that after multiple doses of the standard daily oral tablet, Femara4. The goal is to evaluate how the two forms of letrozole compare in steady-state bioavailability, and to understand the elimination phase of Letrozole SIE after repeated doses. The study has four parts a Screening period, Treatment Period 1 TP1, Treatment Period 2 TP2, and an Extension Period. After screening, participants are randomly assigned to receive either US-sourced or EU-sourced oral Femara4 daily for 14 days in TP1 to reach steady-state drug levels. Then, in TP2, all participants receive quarterly injections of Letrozole SIE to achieve steady-state. A subset of about 60 participants will continue into the Extension Period to further assess drug elimination after multiple doses. Participants will undergo breast imaging before baseline and regular assessments including drug concentration measurements, bone mineral density scans, and monitoring for adverse events and injection site reactions. The primary measure is the area under the concentration-time curve at steady state. Safety and other pharmacokinetic parameters will be tracked from consent through the follow-up visits, which may last up to 421 days for some participants. The total study duration includes screening, treatment, and possible extension periods.
CONDITIONS
Brief Title
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
Research Team
C
Clinical Operations. Laboratorios Farmacéuticos ROVI
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here